The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

Journal of the National Comprehensive Cancer Network found significant disparities based on race, socioeconomic status, and ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Long-term opioid use was common among patients with metastatic disease who were at the end of life, but earlier initiation of long-term use had some benefits.

Researchers from Touro University and Lovelace Biomedical are Developing an Innovative Treatment for Lung Cancer ...

Plasma-based molecular residual disease analysis shows the potential to predict disease recurrence in lung cancer patients by 4.7 months.

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Elevated circulating tumor DNA (ctDNA) fraction and tumor suppressor gene loss are associated with worse prognosis in patients with prostate cancer liver metastases (PCLM), accord ...